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Condensation: Predictive tests for preterm birth (cervical length and quantitative 27 
fetal fibronectin) do not have clinical utility in women with congenital uterine 28 
anomalies related to fusion defects. 29 
 30 
Short Title: Preterm birth prediction by cervical length and quantitative fetal 31 
fibronectin in congenital uterine anomalies. 32 
 33 
AJOG at a GLANCE: 34 
A: Why was the study conducted? 35 
• To assess the performance of current predictive markers of sPTB, quantitative 36 
fetal fibronectin (qfFN) and transvaginal cervical length (CL) measurement in 37 
asymptomatic high-risk women with Congenital Uterine Anomalies (CUA) 38 
• To characterise rates of early delivery by type of CUA 39 
B: What are the key findings? 40 
• CUA, particularly fusion defects, are associated with high rates of late 41 
miscarriage and PTB 42 
• CL and qfFN have utility in prediction of sPTB in women with resorption 43 
defects, however were no better than chance in women with fusion defects. 44 
This is contrary to other high-risk populations.” 45 
C: What does this study add to what is already known?  46 
These findings need to be accounted for when planning antenatal care and have 47 
potential implications for the predictive tests used in sPTB surveillance and 48 
intervention. 49 
 50 
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Bicornuate, Canalisation defects, Cervical length, Congenital uterine anomaly, Fetal 52 
fibronectin, Fusion defect, Unicornuate, Unification defects, Uterus didelphys, 53 
Preterm birth, Resorption defect 54 
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Abstract 58 
 59 
Background: Congenital uterine anomalies (CUA) are associated with late 60 
miscarriage and spontaneous preterm birth (sPTB).  61 
 62 
Objectives: Our aim was to 1) determine the rate of sPTB in each type of CUA and 63 
2) assess the performance of quantitative fetal fibronectin (qfFN) and transvaginal 64 
cervical length (CL) measurement by ultrasound in asymptomatic women with CUA 65 
for the prediction of sPTB at <34 and <37 weeks of gestation.  66 
 67 
Study design: This was a retrospective cohort of women with CUA asymptomatic 68 
for sPTB, from four UK tertiary referral centres (2001-2016).  CUAs were categorised 69 
into fusion (unicornuate, didelphic and bicornuate uteri) or resorption defects 70 
(septate, with or without resection and arcuate uteri), based on pre-pregnancy 71 
diagnosis.  72 
All women underwent serial transvaginal ultrasound CL assessment in the second 73 
trimester (16 to 24 weeks’ gestation); a subgroup underwent qfFN testing from 18 74 
weeks’ gestation. We investigated the relationship between CUA and predictive test 75 
performance for sPTB before 34 and 37 weeks’ gestation.  76 
 77 
Results: Three hundred and nineteen women were identified as having CUA within 78 
our high-risk population. 7% (23/319) delivered spontaneously <34 weeks, and 18% 79 
(56/319) <37 weeks’ gestation. Rates of sPTB by type were: 26% (7/27) for 80 
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5 
unicornuate, 21% (7/34) for didelphic, 16% (31/189) for bicornuate, 13% (7/56) for 81 
septate and 31% (4/13) for arcuate.  82 
80% (45/56) of women who had sPTB <37 weeks did not develop a short CL (<25 83 
mm) during the surveillance period (16-24 weeks). The diagnostic accuracy of short 84 
CL had low sensitivity (20.3) for predicting sPTB <34 weeks.   85 
Cervical Length had ROC AUC of 0.56 (95% CI 0.48 to 0.64) and 0.59 (95% CI 86 
0.55 to 0.64) for prediction of sPTB <34 and 37 weeks’ respectively.  87 
The AUC for CL to predict sPTB <34 weeks was 0.48 for fusion defects (95% CI 0.39 88 
to 0.57) but 0.78 (95% CI 0.66 to 0.91) for women with resorption defects.  89 
Overall quantitative fetal fibronectin had a AUC of 0.63 (95% CI 0.49 to 0.77) and 90 
0.58 (95% CI 0.49 to 0.68) for prediction of sPTB <34 and 37 weeks, respectively.  91 
AUC for prediction of sPTB <37 weeks with qfFN for fusion defects was 0.52 (95% 92 
CI 0.41 to 0.63), but 0.79 (0.63 to 0.95) for women with resorption defects. Results 93 
were similar when women with intervention were excluded.  94 
 95 
Conclusion: Commonly used markers CL and qfFN have utility in prediction of 96 
sPTB in resorption congenital uterine defects but not in fusion defects. This is 97 
contrary to other high-risk populations. These findings need to be accounted for 98 
when planning antenatal care and have potential implications for predictive tests 99 
used in sPTB surveillance and intervention.  100 
 101 
 102 
 103 
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 104 
 105 
Background 106 
The presence of a congenital uterine anomaly (CUA) is a well-established cause of 107 
pregnancy complications, including infertility, recurrent first and second trimester 108 
miscarriages, preterm birth (PTB) with or without preterm pre-labour rupture of 109 
membranes (PPROM), as well as intra-uterine growth restriction, fetal malposition 110 
and caesarean section1–4. The types of CUA are individually associated with varying 111 
degrees of adverse outcomes. 112 
 113 
Formation of the female reproductive tract involves a chain of complex steps, with 114 
differentiation, migration, unification and subsequent canalization of the Müllerian 115 
ducts 5. A deviation anywhere along this stepwise development pathway will result in 116 
a CUA, from arcuate uterus, a subtle variation from normal anatomy, to complete 117 
failure of fusion of the Müllerian ducts, with two discrete cervical canals and uterine 118 
cavities (uterus didelphys). Recognition of CUA is often only noted in the presence of 119 
pathology, e.g. recurrent miscarriage or early delivery. However, in women with 120 
recurrent pregnancy loss, the rate can be as high as 10%6,7. 121 
 122 
While specific CUAs differ in rates of sPTB, and reliable control data to quantify this 123 
is lacking, all are associated with poor reproductive outcomes2, emphasizing the 124 
clinical importance of antenatal surveillance for this group. Identifying those most at 125 
risk of sPTB is the strategy currently employed globally. The value of quantitative 126 
fFN and CL has been proven in large prospective cohorts however reports have 127 
concentrated on asymptomatic singletons with prior preterm birth, late miscarriage or 128 
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cervical surgery. There is limited evidence to support the use of predictive markers in 129 
women with CUAs.  130 
 131 
We prospectively collected serial CL and qfFN data from a large cohort of high-risk 132 
women with congenital uterine anomalies who were asymptomatic for sPTB. Our aim 133 
was to determine the clinical utility of current used predictive markers of sPTB in this 134 
group. 135 
 136 
Study Design 137 
This is a retrospective cohort study of prospectively collected data from 138 
asymptomatic pregnant women with CUAs presenting to high-risk preterm 139 
surveillance clinics (PSC) at four tertiary referral hospitals in London (Queen 140 
Charlotte’s and Chelsea Hospital, St Thomas’ Hospital, Chelsea and Westminster 141 
Hospital and University College London Hospital), over a fifteen-year period (2001 to 142 
2016). Women were included if the diagnosis of a CUA (unicornuate, didelphyic, 143 
bicornuate, septate or arcuate) was made prior to pregnancy by imaging or surgery, 144 
and classified according to the American Fertility Society classification (AFS) (1988) 145 
(currently the American Society of Reproductive Medicine). Surgical repair was 146 
recorded, as were any additional referral risk factors (one or more previous sPTB or 147 
PPROM), previous late miscarriage (14 to 23+6 weeks) or previous cervical surgery).  148 
 149 
As part of routine clinical care within the preterm surveillance clinics, women 150 
underwent serial transvaginal ultrasound (TVUS) surveillance of CL between 16 and 151 
24 weeks’ (second trimester screening). Frequency of surveillance (TV USS and 152 
qfFN) varied between 2 and 4 weeks according to clinical need and continued until 153 
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24weeks, independent of prophylactic intervention (cerclage and/or progesterone). 154 
Elective cervical cerclage was offered as per contemporaneous clinical practice 155 
based on the woman’s previous obstetric history or ultrasound indicated cerclage 156 
based on a short CL in the index pregnancy, defined as a CL <25 mm <24 weeks’ 157 
gestation. In a subgroup of women, qfFN measurement was carried out at each visit 158 
just prior to ultrasound, between 18 and 24 weeks of gestation. FFN samples from 159 
women who reported sexual intercourse within 24 hours or with frank bleeding were 160 
excluded from the analysis according to manufacturer’s instructions (Hologic Inc, 161 
USA).  162 
 163 
Maternal demographic data, serial CL and qfFN measurements, and maternal and 164 
neonatal outcome details were analysed. Women were considered to have had a 165 
spontaneous preterm birth if they had spontaneous onset of labour, or experienced 166 
preterm rupture of membranes and delivered prematurely, regardless of mode of 167 
delivery. Women with iatrogenic delivery before the gestational time point of interest, 168 
twin pregnancies, and those with incomplete outcome data were excluded from the 169 
analysis. We repeated the analysis excluding women with intervention in situ.  170 
 171 
This study was exempt from requiring ethical approval under the UK Health and 172 
Social Care Act 2012, which states that research involving anonymised routinely 173 
collected clinical data is excluded from research ethics committee review.  174 
 175 
Technique of qfFN measurement 176 
During speculum examination, a polyester swab was inserted into the posterior fornix 177 
of the vagina (10 seconds) to collect a sample of cervicovaginal fluid. The swab was 178 
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9 
placed into the test buffer solution and analyzed immediately. An aliquot (200 179 
microliters) of the sample was analyzed using the quantitative Rapid fFN 10Q 180 
analyzer according to manufacturer’ s instructions. All clinicians received appropriate 181 
training to use the analyzers. 182 
 183 
Thresholds of 10 (lower limit of test), 50 (previous standard), and 200 ng/mL (based 184 
on existing literature) were predefined. Quantitative fFN assay results are reported in 185 
units of ng/mL and the result was standardized using purified fetal fibronectin and 186 
A128 measurement with an extinction coefficient = 1.28.  The reliability of the Rapid 187 
10Q analyzer has previously been reported. For the 10Q Assay the intra-assay CV is 188 
5.7% - 7.3% and the intra-assay CV is 5.9% - 7.5%. Experiments that were 189 
performed during product development confirmed a good correlation 190 
between ELISA and 10Q tests (slope = 0.97; r2 = 0.82) [Personal communication 191 
with Jerome Lapointe, Hologic]. 192 
 193 
Technique of cervical length assessment 194 
Serial CL assessment was undertaken in accordance with standardized guidelines 195 
by trained operators.11,12 In summary, the woman was asked to empty her bladder 196 
and then the TVUS probe was inserted into the anterior fornix of the vagina to obtain 197 
a sagittal long axis view of the echogenic endocervical mucosa along the length of 198 
the cervical canal, allowing identification of both the internal and external os. Without 199 
causing undue pressure on the cervix with the probe to avoid falsely elongating it, 200 
the linear distance between the external and internal os was recorded three times in 201 
millimeters over a minimum of three minutes using optimal magnification and zoom 202 
settings and the shortest CL was recorded. Transfundal pressure was exerted for 15 203 
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seconds and subsequent demonstration of a cervical funnel was noted if present. 204 
The shortest total closed CL of three measurements was considered the length for 205 
analysis, with “short” CL defined as less than 25mm.  206 
 207 
Statistical analysis 208 
Descriptive statistics were used to depict the study population. Predictive statistics 209 
were carried out to determine if predictive tests (CL and qfFN) accurately predicted 210 
sPTB <34 and 37weeks’ gestation. Statistical analysis was performed using Stata 211 
14.0. Receiver operating characteristic (ROC) curves were generated and 212 
compared. Data from repeated sampling of the same individuals was analysed. 213 
Therefore clustered bootstrapping with bias correction was used to calculate 214 
confidence intervals for ROC curves (Ng, Grieve & Carpenter, 2013)13. Quantitative 215 
fFN analysis was carried out for a subgroup of women. Due to sample size, 216 
descriptive data alone were generated for this group.  217 
 218 
Results 219 
Four hundred and twenty-nine women with congenital uterine anomalies were 220 
identified in the four high-risk preterm surveillance clinics. One hundred and ten 221 
women were subsequently excluded from analysis as a result of missing outcome 222 
data/uterine anomaly classification (n=91), multiple pregnancy (n=9) and incomplete 223 
qfFN or CL data (n=10).  224 
Of the women included in the analysis (n=319), 9% (27) had unicornuate, 11% (34) 225 
didelphic, 59% (189) bicornuate, 18% (56) septate and 4% (13) arcuate uteri. The 226 
rate of sPTB <37 weeks according to the type of CUA was 26% (7/27) of women with 227 
unicornuate, 21% (7/34) with didelphic, 16% (31/189) with bicornuate, 13% (7/56) 228 
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with septate and 31% (4/13) with arcuate uteri. Overall, the sPTB rate was 7% 229 
(23/319) at <34 weeks and 18% (56/319) at <37 weeks’ gestation.  230 
Two hundred and fifty-seven women (81%, 257/319) had CUA as their sole risk 231 
factor (ie. no additional history of sPTB/late miscarriage or cervical surgery). Rates of 232 
sPTB <37 weeks for this group were as follows: 27% (7/26) for unicornuate, 20% 233 
(6/30) for didelphic, 9% (13/143) for bicornuate, 13% (6/48) for septate and 10% 234 
(1/10) for women with an arcuate uterus (Table 1). 235 
Women with septate uteri had a high rate of previous 1st trimester miscarriage (42%, 236 
15/36). One fifth (21%, 36/173) of women with bicornuate uteri had a previous 237 
history of sPTB. Over 20% (2/9) of the cohort with arcuate uteri had a history of ≥1 238 
previous late miscarriage.  Maternal characteristics relevant to risk of sPTB are 239 
shown in Table 2. 240 
The incidence of sPTB <34 and 37 weeks was 7% (23/319) and 18% (56/319), 241 
although when categorised by anomaly type, this increased to 26% (7/27) for 242 
unicornuate and 31% (4/13) for women with an arcuate uterus <37 weeks (Table 1).  243 
 244 
Cervical length assessment  245 
Three hundred and nineteen women received a total of 955 TVUSS CL 246 
measurements. On average, each women had 2.2 measurements per pregnancy 247 
(range 1 to 6). Twenty-nine women in this high-risk population (9%) were found to 248 
have a short CL (<25 mm), of whom 48% (14/29) delivered <37 weeks.  249 
CL was a poor predictor of sPTB <34 and 37 weeks’ gestation when the cohort was 250 
analysed as a whole (AUC 0.56 (95% CI 0.48 to 0.64) and 0.59 (95% CI 0.55 to 251 
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0.64) respectively) (Table 3), with a low diagnostic sensitivity when a cutoff of <25 252 
mm was used (20.3 and 15.2 for sPTB < 34 and 37 weeks’ respectively). 253 
However, when the cohort was grouped according to fusion or resorption defects, CL 254 
behaved predictably for sPTB <34 weeks in women with resorption (AUC 0.78, 95% 255 
CI 0.66 to 0.91) but not fusion defects (AUC 0.48, 95% CI 0.39 to 0.57) (Figure 1).  256 
CL was predictive for sPTB <34 weeks in women with septate uteri (AUC 0.80, 95% 257 
CI 0.62 to 0.97) (Figure 2) (CL <25 mm: sensitivity 50.0), and in the arcuate group for 258 
delivery <34 and 37 weeks (AUC 0.83, 95% CI 0.51 to 0.98, sensitivity 30.0). Results 259 
did not change after exclusion of women with intervention [septate excluding cervical 260 
cerclage: AUC 0.85 (95% CI 0.79 to 0.91].  261 
Prediction of sPTB at <34 and 37 weeks was poor in women with fusion defects 262 
(AUC 0.48 (95% CI 0.39 to 0.57) and AUC 0.60 (95% CI 0.55 to 0.65). Figure 1. For 263 
specific fusion defects, CL was also not predictive of sPTB <37 weeks (unicornuate 264 
0.48 (95% CI 0.34 to 0.62), didelphic 0.55 (95% CI 0.42 to 0.68) and 0.62 (95% CI 265 
0.56 to 0.69) for bicornuate uteri). Diagnostic accuracy for individual CUA defects 266 
can be seen in Table 4.  267 
Results were similar after excluding women with intervention (cerclage and/or 268 
progesterone) [unicornuate 0.55 (95% 0.39 to 0.74, didelphic 0.55, 95% CI 0.34 to 269 
0.70 and 0.62 (95% CI 0.51 to 0.72) for bicornuate uteri].  270 
 271 
Quantitative fetal fibronectin 272 
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One hundred and fifty five women underwent 793 cervicovaginal qfFN protein 273 
analysis. Overall qfFN had a ROC AUC of 0.63 (95% CI 0.49 to 0.77) and 0.58 (95% 274 
CI 0.49 to 0.68) for prediction of sPTB <34 and 37 weeks, respectively.  275 
We found qfFN to be an accurate test of sPTB <34 and 37 weeks in women with 276 
resorption defects (AUC 0.83 (95% CI 0.62 to 1.00) and AUC 0.79 (95% CI 0.63 to 277 
0.95) respectively) (Figure 3). This did not hold true for fusion defects (AUC for sPTB 278 
<37 weeks 0.52 (95% CI 0.41 to 0.63)).  279 
Management  280 
Over half of the women in our cohort delivered by caesarean section (56%, 281 
124/221), with the highest number in those with didelphic (77%, 17/22) and 282 
unicornuate uteri (73%, 16/22). Sixty per cent (9/15) of women with uterus didelphys 283 
had a fetal malposition at time of delivery (Table 5). In total, 11% (35/319) of women 284 
had a cervical cerclage during their pregnancy. 51% (18/35) were ultrasound 285 
indicated, based on a CL <25mm at gestation <24 weeks. 11% of women were 286 
prescribed progesterone during their pregnancy, although we only have data on 287 
progesterone prescribing practices for 138/319 women (Table 6). 80% (45/56) of 288 
women who delivered spontaneously <37 weeks’ did not develop a short CL during 289 
our surveillance period (16 to 24 weeks’). 290 
 291 
 292 
 293 
 294 
 295 
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 296 
 297 
Comment 298 
 299 
Principle Findings: 300 
Commonly used markers, CL and qfFN, have utility in prediction of sPTB in 301 
resorption congenital uterine defects but not in fusion defects. This is contrary to 302 
other high-risk populations. 80% (45/56) of women who went into spontaneous 303 
labour preterm did not develop a short CL during the antenatal surveillance period.  304 
 305 
In our cohort, 21% (7/34) women with a didelphic uterus (a fusion defect) delivered 306 
<37 weeks’ gestation, and 8% (3/34) <34 weeks’ gestation. Early pregnancy CL 307 
measurement was no better than chance at predicting delivery <37 weeks, with poor 308 
AUC, sensitivity and negative predictive value.  309 
 310 
Asymptomatic qfFN screening in our whole cohort was a poor predictor of delivery at 311 
<34 weeks’ gestation. This was confirmed for fusion defects (<34 weeks AUC 0.55, 312 
95% CI 0.39 to 0.70, <37 weeks AUC 0.52, 95% CI 0.41 to 0.63). This is contrary to 313 
other cohorts at high risk of sPTB (e.g. history of late miscarriage) and therefore it is 314 
important that clinicians are aware of this when planning antenatal surveillance and 315 
choosing predictive tests for sPTB.  316 
 317 
Clinical Implications: 318 
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Whilst women with CUA are considered to be at high-risk of sPTB, data correlating 319 
individual congenital uterine anomaly and outcome is limited. The existing strategy 320 
used for prediction of sPTB in women at high-risk for other reasons is recognised to 321 
be inadequate. An understanding of the increased risk posed to women with each 322 
type of anomaly will help to determine their subsequent antenatal management 323 
pathways, and the appropriate diagnostic tests. In this study we report the accuracy 324 
of predictive markers of sPTB in asymptomatic high-risk women with CUA, 325 
correlating both CL and qfFN with individual defect types and categorised according 326 
to resorption or fusion defects.   327 
 328 
The pathophysiological processes underlying early delivery in CUA cases remain 329 
uncertain. Deficiency in the endometrium overlying any anatomical variation, for 330 
example the septum, may provide a suboptimal site for implantation, disorderly and 331 
decreased blood supply insufficient to support placentation14 and embryonic growth. 332 
Other potential hypothesized mechanisms include abnormal myometrial architecture 333 
producing uncoordinated uterine contractions15 or reduced uterine capacity,16 334 
affecting stretch. The structure of the cervix is integral to the maintenance of 335 
pregnancy;17 disruption in cervical architecture, particularly the internal cervical os 336 
may account for increased rates of sPTB. 337 
 338 
The difference in predictive test performance between fusion and resorption groups 339 
may be related to the underlying mechanism of preterm birth. In women with 340 
resorption defects (septate and arcuate uterus), predictive markers performed as 341 
seen in other high-risk populations; both CL and qfFN were useful predictors of sPTB 342 
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<34 and 37 weeks’ gestation. Resorption defects have relatively normal uterine 343 
architecture. By definition an arcuate uterus has an intrauterine indentation of less 344 
than 1cm and therefore it is plausible that it does not impact on either the cause of 345 
preterm delivery or the mechanism by which markers CL and qfFN predict delivery. 346 
 347 
For more severe structural anomalies, such as unicornuate or uterus didelphys, the 348 
converse is likely to be true, and poor pregnancy outcome is hypothesized to be 349 
related to stretch effects secondary to altered uterine architecture, decreased muscle 350 
mass and abnormal cervical architecture, with or without abnormal uterine 351 
vasculature18. If the cervix plays no part in the aetiology of labour onset, it may not 352 
predict delivery in this group. Further research needs to focus on novel predictive 353 
markers in this high-risk group. 354 
 355 
Late miscarriage and preterm birth are frequently thought to be associated with 356 
inflammation and infection. Recent literature has linked true positive fFN results with 357 
placental inflammation, hypothesised to disturb the decidua-chorionic interface, 358 
threatening the integrity of the maternal-fetal interface and leading to the release of 359 
fFN into the cervico-vaginal secretions where it is detected19. Quantitative fFN is a 360 
leading predictor of sPTB and its value as a screening tool for high-risk 361 
asymptomatic women is increasingly recognised8. However, abnormal myometrium 362 
and stretch effects may not cause this same release of fFN, which may account for 363 
its poor predictive value in fusion defects. 364 
 365 
Strengths and Weaknesses: 366 
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Three previous studies reported the use of CL measurement in women with CUA20–367 
22
, and one has evaluated the addition of qualitative fFN23. Consensus concluded 368 
that short CL on TVUS correlates with increased risk of sPTB in women with CUA. 369 
However these studies do not comment on the differences between types of CUA. 370 
They are small (the largest 120 women23 compared to 319 reported here) and 371 
therefore do not have sufficient power for this analysis. Increased sample size 372 
allowed our analysis to discern a difference in predictive tests, qfFN and CL, 373 
between fusion and resorption defects, rather than examining the cohort as one 374 
heterogeneous group.  375 
 376 
Consistent with our findings, Airoldi et al (2005) highlighted no cervical shortening in 377 
the two women with didelphic uteri (n=2/11) who went on to deliver preterm (n=11)20. 378 
The two studies describing CL measurement both extended their sampling windows 379 
up to 3021 and 3223 weeks respectively, and developed a new cut off of 30mm, 380 
based on their individual data set (n=52)21. With this increased sampling window 381 
Crane et al report 100% sensitivity for a CL cut off of 30mm. As this was only 3 out of 382 
3 events identified and both studies were sampling outside of current clinical 383 
guidelines, we believe our data supersedes this.   384 
 385 
It is important to acknowledge the limitations of our study. Women and healthcare 386 
providers were not blinded to CL and qfFN assessments. The study population 387 
included women who were referred to a preterm birth surveillance clinics for high-risk 388 
monitoring. We do not know the number of women with a uterine anomaly who were 389 
not referred for asymptomatic screening. Also while this larger cohort allows us to 390 
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draw some conclusions about individual subgroups, we recognise we do not have 391 
adequate power to undertake further analysis investigating the additive value of qfFN 392 
and CL. Future research in women with resorption defects would help understand 393 
the synergies between predictive tests, as well as seeking the ideal surveillance 394 
window and CL and qfFN cut offs for this population. 395 
 396 
A further limitation was that septate uteri were a small group in this study. The data 397 
did not lend itself to biological plausibility with regard to separating the groups into 398 
those who had had surgical removal of their septum, and those who had not, and 399 
therefore we highlight this as an area that would benefit from future research. 400 
Arcuate uteri also appeared particularly high-risk in our cohort, however the numbers 401 
were small and in this group all but one case had additional risk factors. Therefore 402 
CUA may have been an incidental finding and a significant proportion of preterm 403 
deliveries may be due to aetiology unrelated to CUA, for example infection and 404 
inflammation.  405 
 406 
If a short cervix (CL <25mm) was detected within the surveillance period, an 407 
ultrasound-indicated cerclage may have been carried out, depending on local 408 
hospital clinical practice. Repeat analysis excluding women with intervention 409 
(cerclage and/or progesterone) confirmed predictive markers were no better than 410 
chance in women with fusion defects but have clinical utility in women with resorption 411 
defects. The literature confirms the continued value of CL measurement as a reliable 412 
predictor of sPTB with cerclage in situ, and 80% of women who delivered preterm 413 
spontaneous did not develop a short CL during the surveillance period. Only 6% 414 
(18/319) of our total cohort had an ultrasound-indicated cerclage.   415 
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 416 
Conclusions and future research implications 417 
Our findings suggest different aetiological contributions to the pathophysiology of 418 
sPTB in CUA, which do not follow the predictable pattern of cervical shortening and 419 
dilatation seen in women who deliver early due to inflammation and infection. This 420 
needs to be accounted for when planning antenatal care, with potential implications 421 
for sPTB surveillance and intervention.  422 
  423 
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Table 1: Pregnancy outcome in women with congenital uterine anomaly 528 
Pregnancy 
Outcome 
Cohort 
(n=319) 
Unicornuate 
(n=27) 
Didelphys 
(n=34) 
Bicornuate 
(n=189) 
Septate 
(n=56) 
Arcuate 
(n=13) 
 
sPTB <37 
weeks 
 
17.6% 
(56) 
 
25.9% 
(7) 
 
20.6% 
(7) 
 
16.4% 
(31) 
 
12.5% 
(7) 
 
30.8% 
(4) 
 
sPTB < 34 
weeks 
 
 
7.2% 
(23) 
 
3.7% 
(1) 
 
8.8% 
(3) 
 
6.3% 
(12) 
 
5.4% 
(3) 
 
30.8% 
(4) 
 
sPTB < 37 
weeks 
when CUA 
is the sole 
risk factor 
 
 
12.8% 
(33/257) 
 
26.9% 
(7/26) 
 
 
20.0% 
(6/30) 
 
9.1% 
(13/143) 
 
12.5% 
(6/48) 
 
10% 
(1/10) 
 529 
 530 
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 535 
 536 
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 544 
 545 
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 547 
 548 
 549 
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Table 2: Maternal Characteristics of women with congenital uterine anomaly 551 
Maternal 
Characteristic 
(n, %) 
Cohort 
(n=319) 
 
Unicornuate 
(27, 8.5%) 
 
Didelphys 
(34, 10.7%) 
Bicornuate 
(189, 59.3%) 
Septate 
(56, 17.6%) 
Arcuate 
(13, 4%) 
 
Primiparous 
 
 
55.2% 
(176) 
 
 
66.7% 
(18) 
 
 
67.6% 
(23) 
 
 
47.6% 
(90) 
 
 
 66.1% 
(37) 
 
 
61.5% 
(8) 
 
 
Multiparous 
 
 
 44.8% 
(143) 
 
 
33.3% 
(9) 
 
 
32.4% 
(11) 
 
 
52.4% 
(99) 
 
 
33.9% 
(19) 
 
 
38.5% 
(5) 
 
 
Previous 
term delivery 
 
35.0%  
(50/143) 
 
 
22.2% 
(2/9) 
 
36.4% 
(4/11) 
 
38.4% 
(38/99) 
 
26.3% 
(5/19) 
 
20% 
(1/5) 
 
Previous first 
trimester 
miscarriage 
 
 
31.9% 
(61/191) 
 
30.8% 
(4/13) 
 
30.4% 
(7/23) 
 
29.9% 
(35/117) 
 
41.7% 
(15/36) 
 
0% 
(0/2) 
 
Previous 
sPTB  
< 37 weeks 
 
15.9% 
(45/283) 
 
 
0% 
(0/22) 
 
12.5% 
(4/32) 
 
20.8% 
(36/173) 
 
8.5% 
(4/47) 
 
11.1% 
(1/9) 
 
Previous mid-
trimester loss  
 
9.2% 
(26/283) 
 
 
4.5% 
(1/22) 
 
3.1% 
(1/32) 
 
10.4% 
(18/173) 
 
8.5% 
(4/47) 
 
22.2% 
(2/9) 
 
Previous 
cervical 
surgery 
 
 
13.1% 
(37/283) 
 
 
9.1% 
(2/22) 
 
3.1% 
(1/32) 
 
14.5% 
(25/173) 
 
14.9% 
(7/47) 
 
22.2% 
(2/9) 
 
Ethnicity 
1- White 
2- Asian 
3- Black 
4- Unknown 
 
 
 
48.6% (155) 
3.4% (11) 
5.3% (17) 
42.6% (136) 
 
 
 
8.4% (13) 
18.1% (2) 
0 
8.8% (12) 
 
 
 
11.6% (18) 
18.1% (2) 
0 
10.3% (14) 
 
 
58.1% (90) 
36.3% (4) 
82.4% (14) 
60.0% (81) 
 
 
 
17.4% (27) 
27.3% (3) 
5.9% (1) 
18.4% (25) 
 
 
5.0% (7) 
0 
11.8% (2) 
2.9% (4) 
 
BMI 
(median, IQR) 
 
 
23.1 
21.0 – 39.0 
 
23.5 
22.3 – 30.0 
 
24.0 
22.4– 33.8 
 
23.0 
20.9 – 39.0 
 
23.0 
20.6-36.8 
 
23.9 
21.0 – 36.7 
 
Results given as % (n) or median [interquartile range] 552 
 553 
 554 
 555 
 556 
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Table 3: Accuracy of qfFN and CL for the prediction of sPTB   560 
 561 
 
Type of anomaly 
CL prediction qfFN prediction 
ROC AUC  
95% confidence intervals 
ROC AUC 
95% confidence intervals 
Whole cohort (n=319) 
sPTB<34weeks 
sPTB<37weeks 
 
0.56 
0.59 
 
0.48 to 0.64 
0.55 to 0.64 
 
0.63 
0.58 
 
0.49 to 0.77 
0.49 to 0.68 
Fusion defects  
sPTB<34weeks 
sPTB<37weeks 
 
0.48 
0.60 
 
0.39 to 0.57 
0.55 to 0.65 
 
0.55 
0.52 
 
0.39 to 0.70 
0.41 to 0.63 
Resorption defects 
sPTB<34weeks 
sPTB<37weeks 
 
0.78 
0.66 
 
0.66 to 0.91 
0.55 to 0.78 
 
0.83 
0.79 
 
0.62 to 1.00 
0.63 to 0.95 
 562 
 563 
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 566 
 567 
 568 
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 570 
 571 
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 573 
 574 
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 576 
 577 
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Table 4: Accuracy of CL for the prediction of sPTB in subgroups 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 
Type of anomaly 
 
ROC AUC  
95% confidence intervals 
Unicornuate (n=27) 
sPTB<34weeks 
sPTB<37weeks 
 
0.56 
0.48 
 
0.32 to 0.80 
0.34 to 0.62 
Didelphys (n=34) 
sPTB<34weeks 
sPTB<37weeks 
 
0.50 
0.55 
 
0.31 to 0.70 
0.42 to 0.68 
Bicornuate (n=189) 
sPTB<34weeks 
sPTB<37weeks 
 
0.46 
0.62 
 
0.35 to 0.56 
0.56 to 0.69 
Septate (n=56) 
sPTB<34weeks 
sPTB<37weeks 
 
0.80 
0.61 
 
0.62 to 0.97 
0.47 to 0.76 
Arcuate (n=13) 
sPTB<34weeks 
sPTB<37weeks 
 
0.79 
0.79 
 
0.51 to 0.98 
0.51 to 0.98 
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 594 
Table 5: Pregnancy outcome in women with congenital uterine anomaly 595 
Pregnancy 
Outcome 
Cohort 
(n=319) 
Unicornuate 
(n=27) 
Didelphys 
(n=34) 
Bicornuate 
(n=189) 
Septate 
(n=56) 
Arcuate 
(n=13) 
Primiparous 
women with 
sPTB <37 
weeks 
 
13%  
(22) 
 
 
17% (3) 
 
 
26% (6) 
 
8% (7) 
 
 
14% (5) 
 
 
13% (1) 
Multiparous 
women with 
sPTB <37 
weeks 
 
23%  
(33) 
 
44% (4) 
 
 
0% (0) 
 
 
27% (24) 
 
 
11% (2) 
 
60% (3) 
 
 
Rate of 
caesarean 
section 
 
 
56% 
(124/221) 
 
72.7% 
(16/22) 
 
 
77.3% 
(17/22) 
 
 
55.6% 
(70/126) 
 
 
42.1% 
(16/38) 
 
38.5% 
(5/13) 
 
Fetal 
malposition  
 
 
32% 
(39/121) 
 
30.8% 
(4/13) 
 
60% 
(9/15) 
 
30.8% 
(16/52) 
 
35.7% 
(10/28) 
 
0% 
(0/13) 
 
NICU 
admissions 
 
 
16% 
(20/123) 
 
25% 
(1/4) 
 
0% 
(0/12) 
 
 
15.6% 
(12/77) 
 
20% 
(4/20) 
 
30% 
(3/10) 
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 613 
Table 6: Antenatal management in asymptomatic women with CUA  614 
Pregnancy 
Outcome 
Cohort 
 
(n=319) 
Unicornuate 
 
(n=27) 
Didelphys 
 
(n=34) 
Bicornuate 
 
(n=189) 
Septate 
 
(n=56) 
Arcuate 
 
(n=13) 
 
Cerclage 
 
11.0%  
(35/319) 
 
 
11.1% 
(3/27) 
 
14.7% 
(5/34) 
 
 10.1% 
(19/189) 
 
12.5% 
(7/56) 
 
7.7% 
(1/13) 
 
 
Ultrasound 
indicated 
 
 
51.4% 
(18/35) 
 
7.4% 
(2/27) 
 
5.8% 
(2/34) 
 
5.8% 
 (11/189) 
 
3.6% 
(2/56) 
 
7.7% 
(1/13) 
sPTB <37/40 23.5% (5/18) 0% (0/2) 50% (1/2)  (5/11) 50% (1/2) 100% (1/1) 
sPTB <34/40 23.5% (5/18) 50% (1/2) 50% (1/2)  (1/11) 50% (1/2) 100% (1/1) 
 
History indicated 
 
 
48.6% 
(17/35) 
 
 
3.7% 
(1/27) 
 
8.8% 
(3/34) 
 
4.2% 
(8/189) 
 
8.9% 
(5/56) 
 
0% 
(0/13) 
sPTB <37/40 23.5% (4/17) 0% (0/1) 33.3% (1/3) 25% (2/8) 20% (1/5) 0% (0/13) 
sPTB <34/40 17.6% (3/17) 0% (0/1) 33.3% (1/3) 12.5% (1/8) 20% (1/5) 0% (0/13) 
 
sPTB without 
short CL 
 
 
80.4% 
(45/56) 
 
85.7% 
(6/7) 
 
85.7% 
(6/7) 
 
90.3% 
(28/31) 
 
57.1% 
(4/7) 
 
 
25% 
(1/4) 
sPTB <37/40 18% (56/319) 25.9% (7/27) 20.8% (7/34) 16.4% (31/189) 12.5% (7/56) 30.7% (4/13) 
 
Progesterone 
 
 
10.8% 
(15/138) 
 
 
30.8% 
(4/13) 
 
7.7% 
(1/13) 
 
7.9% 
(6/76) 
 
13.8% 
(4/29) 
 
0% 
(0/6) 
 615 
 616 
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 623 
Figure 1: TVUSS CL to predict sPTB <34weeks in CUA grouped by fusion or 624 
resorption defect 625 
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Figure 2: TVUSS CL to predict sPTB <34 weeks by type of CUA defect  635 
 636 
*using binomial modeling 637 
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 645 
Figure 3: Quantitative fetal fibronectin to predict sPTB <37 weeks grouped by 646 
fusion or resorption defect 647 
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Table 1: Pregnancy outcome in women with congenital uterine anomaly 
Pregnancy 
Outcome 
Cohort 
(n=319) 
Unicornuate 
(n=27) 
Didelphys 
(n=34) 
Bicornuate 
(n=189) 
Septate 
(n=56) 
Arcuate 
(n=13) 
 
sPTB <37 
weeks 
 
17.6% 
(56) 
 
25.9% 
(7) 
 
20.6% 
(7) 
 
16.4% 
(31) 
 
12.5% 
(7) 
 
30.8% 
(4) 
 
sPTB < 34 
weeks 
 
 
7.2% 
(23) 
 
3.7% 
(1) 
 
8.8% 
(3) 
 
6.3% 
(12) 
 
5.4% 
(3) 
 
30.8% 
(4) 
 
sPTB < 37 
weeks 
when CUA 
the sole 
risk factor 
 
 
12.8% 
(33/257) 
 
26.9% 
(7/26) 
 
 
20.0% 
(6/30) 
 
9.1% 
(13/143) 
 
12.5% 
(6/48) 
 
10% 
(1/10) 
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Table 2: Maternal Characteristics of women with congenital uterine 
anomaly 
Maternal 
Characteristic 
(n, %) 
Cohort 
(n=319) 
 
Unicornuate 
(27, 8.5%) 
 
Didelphys 
(34, 10.7%) 
Bicornuate 
(189, 59.3%) 
Septate 
(56, 17.6%) 
Arcuate 
(13, 4%) 
 
Primiparous 
 
 
55.2% 
(176) 
 
 
66.7% 
(18) 
 
 
67.6% 
(23) 
 
 
47.6% 
(90) 
 
 
 66.1% 
(37) 
 
 
61.5% 
(8) 
 
 
Multiparous 
 
 
 44.8% 
(143) 
 
 
33.3% 
(9) 
 
 
32.4% 
(11) 
 
 
52.4% 
(99) 
 
 
33.9% 
(19) 
 
 
38.5% 
(5) 
 
 
Previous 
term delivery 
 
35.0%  
(50/143) 
 
 
22.2% 
(2/9) 
 
36.4% 
(4/11) 
 
38.4% 
(38/99) 
 
26.3% 
(5/19) 
 
20% 
(1/5) 
 
Previous first 
trimester 
miscarriage 
 
 
31.9% 
(61/191) 
 
30.8% 
(4/13) 
 
30.4% 
(7/23) 
 
29.9% 
(35/117) 
 
41.7% 
(15/36) 
 
0% 
(0/2) 
 
Previous 
sPTB  
< 37 weeks 
 
15.9% 
(45/283) 
 
 
0% 
(0/22) 
 
12.5% 
(4/32) 
 
20.8% 
(36/173) 
 
8.5% 
(4/47) 
 
11.1% 
(1/9) 
 
Previous mid-
trimester loss  
 
9.2% 
(26/283) 
 
 
4.5% 
(1/22) 
 
3.1% 
(1/32) 
 
10.4% 
(18/173) 
 
8.5% 
(4/47) 
 
22.2% 
(2/9) 
 
Previous 
cervical 
surgery 
 
13.1% 
(37/283) 
 
 
9.1% 
(2/22) 
 
3.1% 
(1/32) 
 
14.5% 
(25/173) 
 
14.9% 
(7/47) 
 
22.2% 
(2/9) 
 
Ethnicity 
1- White 
2- Asian 
3- Black 
4- Unknown 
 
 
 
48.6% (155) 
3.4% (11) 
5.3% (17) 
42.6% (136) 
 
 
 
8.4% (13) 
18.1% (2) 
0 
8.8% (12) 
 
 
 
11.6% (18) 
18.1% (2) 
0 
10.3% (14) 
 
 
58.1% (90) 
36.3% (4) 
82.4% (14) 
60.0% (81) 
 
 
 
17.4% (27) 
27.3% (3) 
5.9% (1) 
18.4% (25) 
 
 
5.0% (7) 
0 
11.8% (2) 
2.9% (4) 
 
BMI 
(median, IQR) 
 
 
23.1 
21.0 – 39.0 
 
23.5 
22.3 – 30.0 
 
24.0 
22.4– 33.8 
 
23.0 
20.9 – 39.0 
 
23.0 
20.6-36.8 
 
23.9 
21.0 – 36.7 
 
Results given as % (n) or median [interquartile range] 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3: Accuracy of qfFN and CL for the prediction of sPTB   
 
 
Type of anomaly 
CL prediction qfFN prediction 
ROC AUC  
95% confidence intervals 
ROC AUC 
95% confidence intervals 
Whole cohort (n=319) 
sPTB<34weeks 
sPTB<37weeks 
 
0.56 
0.59 
 
0.48 to 0.64 
0.55 to 0.64 
 
0.63 
0.58 
 
0.49 to 0.77 
0.49 to 0.68 
Fusion defects  
sPTB<34weeks 
sPTB<37weeks 
 
0.48 
0.60 
 
0.39 to 0.57 
0.55 to 0.65 
 
0.55 
0.52 
 
0.39 to 0.70 
0.41 to 0.63 
Resorption defects 
sPTB<34weeks 
sPTB<37weeks 
 
0.78 
0.66 
 
0.66 to 0.91 
0.55 to 0.78 
 
0.83 
0.79 
 
0.62 to 1.00 
0.63 to 0.95 
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Table 4: Accuracy of CL for the prediction of sPTB in subgroups 
 
 
 
 
 
Type of anomaly 
 
ROC AUC  
95% confidence intervals 
Unicornuate (n=27) 
sPTB<34weeks 
sPTB<37weeks 
 
0.56 
0.48 
 
0.32 to 0.80 
0.34 to 0.62 
Didelphys (n=34) 
sPTB<34weeks 
sPTB<37weeks 
 
0.50 
0.55 
 
0.31 to 0.70 
0.42 to 0.68 
Bicornuate (n=189) 
sPTB<34weeks 
sPTB<37weeks 
 
0.46 
0.62 
 
0.35 to 0.56 
0.56 to 0.69 
Septate (n=56) 
sPTB<34weeks 
sPTB<37weeks 
 
0.80 
0.61 
 
0.62 to 0.97 
0.47 to 0.76 
Arcuate (n=13) 
sPTB<34weeks 
sPTB<37weeks 
 
0.79 
0.79 
 
0.51 to 0.98 
0.51 to 0.98 
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Table 5: Pregnancy outcome in women with congenital uterine anomaly 
Pregnancy 
Outcome 
Cohort 
(n=319) 
Unicornuate 
(n=27) 
Didelphys 
(n=34) 
Bicornuate 
(n=189) 
Septate 
(n=56) 
Arcuate 
(n=13) 
Primiparous 
women with 
sPTB <37 
weeks 
 
13%  
(22) 
 
 
17% (3) 
 
 
26% (6) 
 
8% (7) 
 
 
14% (5) 
 
 
13% (1) 
Multiparous 
women with 
sPTB <37 
weeks 
 
23%  
(33) 
 
44% (4) 
 
 
0% (0) 
 
 
27% (24) 
 
 
11% (2) 
 
60% (3) 
 
 
Rate of 
caesarean 
section 
 
 
56% 
(124/221) 
 
72.7% 
(16/22) 
 
 
77.3% 
(17/22) 
 
 
55.6% 
(70/126) 
 
 
42.1% 
(16/38) 
 
38.5% 
(5/13) 
 
Fetal 
malposition  
 
 
32% 
(39/121) 
 
30.8% 
(4/13) 
 
60% 
(9/15) 
 
30.8% 
(16/52) 
 
35.7% 
(10/28) 
 
0% 
(0/13) 
 
NICU 
admissions 
 
 
16% 
(20/123) 
 
25% 
(1/4) 
 
0% 
(0/12) 
 
 
15.6% 
(12/77) 
 
20% 
(4/20) 
 
30% 
(3/10) 
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Table 6: Antenatal management in asymptomatic women with CUA  
Pregnancy 
Outcome 
Cohort 
 
(n=319) 
Unicornuate 
 
(n=27) 
Didelphys 
 
(n=34) 
Bicornuate 
 
(n=189) 
Septate 
 
(n=56) 
Arcuate 
 
(n=13) 
 
Cerclage 
 
11.0%  
(35/319) 
 
 
11.1% 
(3/27) 
 
14.7% 
(5/34) 
 
 10.1% 
(19/189) 
 
12.5% 
(7/56) 
 
7.7% 
(1/13) 
 
 
Ultrasound 
indicated 
 
 
51.4% 
(18/35) 
 
7.4% 
(2/27) 
 
5.8% 
(2/34) 
 
5.8% 
 (11/189) 
 
3.6% 
(2/56) 
 
7.7% 
(1/13) 
sPTB <37/40 23.5% (5/18) 0% (0/2) 50% (1/2)  (5/11) 50% (1/2) 100% (1/1) 
sPTB <34/40 23.5% (5/18) 50% (1/2) 50% (1/2)  (1/11) 50% (1/2) 100% (1/1) 
 
History indicated 
 
 
48.6% 
(17/35) 
 
 
3.7% 
(1/27) 
 
8.8% 
(3/34) 
 
4.2% 
(8/189) 
 
8.9% 
(5/56) 
 
0% 
(0/13) 
sPTB <37/40 23.5% (4/17) 0% (0/1) 33.3% (1/3) 25% (2/8) 20% (1/5) 0% (0/13) 
sPTB <34/40 17.6% (3/17) 0% (0/1) 33.3% (1/3) 12.5% (1/8) 20% (1/5) 0% (0/13) 
 
sPTB without 
short CL 
 
 
80.4% 
(45/56) 
 
85.7% 
(6/7) 
 
85.7% 
(6/7) 
 
90.3% 
(28/31) 
 
57.1% 
(4/7) 
 
 
25% 
(1/4) 
sPTB <37/40 18% (56/319) 25.9% (7/27) 20.8% (7/34) 16.4% (31/189) 12.5% (7/56) 30.7% (4/13) 
 
Progesterone 
 
 
10.8% 
(15/138) 
 
 
30.8% 
(4/13) 
 
7.7% 
(1/13) 
 
7.9% 
(6/76) 
 
13.8% 
(4/29) 
 
0% 
(0/6) 
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Figure 1: TVUSS CL to predict sPTB <34weeks in CUA grouped by 
fusion or resorption defect 
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Figure 2: TVUSS CL to predict sPTB <34 weeks by type of CUA defect  
 
*using binomial modeling 
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Figure 3: Quantitative fetal fibronectin to predict sPTB <37 weeks 
grouped by fusion or resorption defect 
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